3 results
Primary objective: The primary objective of this study is to compare the preoperative radiotracer kinetics (rate of injection site clearance and rate of SLN uptake) for Lymphoseek and 99mTc-Nanocoll. Secondary objectives: * To compare the number of…
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
Cohorts 1, 2, and 3 only:The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3)…